These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35232410)

  • 21. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
    Kim AY; Frantz S; Brower J; Akhter N
    J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis.
    Devcic Z; Rosenberg J; Braat AJ; Techasith T; Banerjee A; Sze DY; Lam MG
    J Nucl Med; 2014 Sep; 55(9):1404-10. PubMed ID: 25012459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
    Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
    J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
    Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of 90Y-Radioembolization in Metastatic Colorectal Cancer Depending on the Primary Tumor Side.
    Schindler P; Masthoff M; Harders F; Schmidt HH; Stegger L; Pascher A; Rahbar K; Wildgruber M; Köhler M
    Dig Dis; 2021; 39(4):351-357. PubMed ID: 33142291
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
    Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB
    J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
    Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
    Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
    Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer.
    Davisson NA; Bercu ZL; Friend SC; Paplomata E; Ermentrout RM; Newsome J; Majdalany BS; Kokabi N
    J Vasc Interv Radiol; 2020 Jun; 31(6):925-933. PubMed ID: 32307310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry.
    Robinson TJ; Du L; Matsuoka L; Sze DY; Kennedy AS; Gandhi RT; Kouri BE; Collins ZS; Kokabi N; Grilli CJ; Wang EA; Lee JS; Brown DB
    J Vasc Interv Radiol; 2023 Apr; 34(4):694-701.e3. PubMed ID: 36509236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yttrium-90 radiation segmentectomy for hepatic metastases: A multi-institutional study of safety and efficacy.
    Padia SA; Johnson GE; Agopian VG; DiNorcia J; Srinivasa RN; Sayre J; Shin DS
    J Surg Oncol; 2021 Jan; 123(1):172-178. PubMed ID: 32944980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
    King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
    Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
    Jia Z; Wang W
    Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
    Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
    Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.